A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2

NCT ID: NCT03278158

Last Updated: 2019-03-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-09-18
• Study Completion Date: 2018-11-13

Brief Summary

This is a single-dose dose escalation trial in a randomised, single-blind, placebo-controlled group-comparison design to investigate the safety and tolerability of XEN-D0501 in subjects with diabetes mellitus type 2 where life style changes and treatment with metformin has failed to effectively reduce blood glucose concentrations.

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Placebo

Subjects in the placebo arm will receive a single oral tablet containing no active drug.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects in the placebo arm will receive a single oral tablet containing no active drug.

XEN-D0501, 1 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet

Group Type: EXPERIMENTAL

XEN-D0501, 1 mg/tablet

Intervention Type: DRUG

Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet

XEN-D0501, 2 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet. Discontinued after 2 patients due to good safety. Escalation to higher dose levels in whole study (1, 2 and 4 mg changed to 1, 4 and 8 mg)

Group Type: EXPERIMENTAL

XEN-D0501, 2 mg/tablet

Intervention Type: DRUG

Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet

XEN-D0501, 4 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet

Group Type: EXPERIMENTAL

XEN-D0501, 4 mg/tablet

Intervention Type: DRUG

Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet

XEN-D0501, 8 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet

Group Type: EXPERIMENTAL

XEN-D0501, 8 mg/tablet

Intervention Type: DRUG

Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet

Interventions

Placebo

Subjects in the placebo arm will receive a single oral tablet containing no active drug.

Intervention Type: DRUG

XEN-D0501, 1 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet

Intervention Type: DRUG

XEN-D0501, 2 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet

Intervention Type: DRUG

XEN-D0501, 4 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet

Intervention Type: DRUG

XEN-D0501, 8 mg/tablet

Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The subject must give his/her signed and dated informed consent before any trial-related activities. Trial-related activities are any procedures that would not have been performed during the normal management of the subject.

2. Diagnosis of type 2 diabetes mellitus

3. In treatment with metformin, but no other anti-diabetic drugs

4. In treatment with an ACE-inhibitor but no other anti-hypertensive drugs

5. HbA1C (glycosylated haemoglobin A1C) 6.5-10 %

6. Age between 30 and 70 years (both inclusive).

Exclusion Criteria

1. A subject with a history of significant multiple drug allergies or with a known or suspected allergy to the trial product or any medicine chemically related to the trial product, as judged by the Investigator.

2. A subject who has a supine blood pressure at screening (including those on anti-hypertensives), after resting for 5 min, outside the range of 90-140 mmHg systolic or 50-90 mmHg diastolic (excluding white-coat hypertension; therefore, if a repeated measurement on a second screening visit shows values within the range, the subject can be included in the trial).

3. A subject who is in pharmacological treatment of hypertension if the current treatment includes other than an ACE-inhibitor

4. A subject who has a clinically significant abnormal ECG at screening, as judged by the investigator.

5. A subject who has participated in any other trials involving investigational products within the 3 months preceding the start of dosing.

6. A subject who has donated any blood or plasma in the past month or in excess of 500 mL within the 3 months preceding screening.

7. A subject who has a significant history of alcoholism or drug/chemical abuse as per investigator's judgement, or who has a positive result in the urine drug/alcohol screen at screening visit.

8. A subject who smokes more than 5 cigarettes, or the equivalent, per day and is unable to refrain from smoking during the in-house periods as determined by the Investigator.

9. A subject with mental incapacity or language barriers which preclude adequate understanding or cooperation, who is unwilling to participate in the trial, or who in the opinion of their general practitioner or the Investigator should not participate in the trial.

10. Surgery or trauma with significant blood loss within the last 2 months prior to dosing.

11. A subject with a history of or presence of cancer, or any clinically significant, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (with the exception of diabetes mellitus type 2 and euthyroid struma), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders.

12. Cardiac problems defined as: decompensated heart failure (New York Heart Association (NYHA) class III and IV) at any time and/or angina pectoris and/or acute myocardial infarction within the last 12 months.

13. A subject with a clinically significant abnormal haematology or biochemistry tests at screening visit, as judged by the Investigator considering the underlying disease.

14. Current treatment with drugs known to interfere with glucose metabolism such as systemic corticoids and monoamine oxidase inhibitors (MAO) inhibitors.

15. A subject who has proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.

16. Haemoglobin < 6.2 mmol/l, total leukocyte count < 3.0 x 109/l, thrombocytes <100 x 109/l, serum creatinine levels ≥ 126 µmol/l (male) or ≥ 111 µmol/l (female), bilirubin > 3 x ULN, alanine aminotransferase > 2 x the upper limit of normal (ULN), alkaline phosphatase > 2 x ULN, one re-test within a week is permitted.

17. Previous participation (randomisation) in this trial.

18. Any condition that would interfere with trial participation or evaluation of results, as judged by the investigator and/or sponsor

19. Recurrent major hypoglycaemia or hypoglycaemic unawareness, as judged by the Investigator.

20. Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (Adequate contraceptive measures include sterilisation, hormonal intrauterine devices, oral hormonal contraceptives (p-pills), implantants, transdermal patches, p-ring or depot injection, sexual abstinence or vasectomised partner). A male subject who is sexually active and has not been surgically sterilised must be informed that he must ensure that his partner practices effective contraception, as stated above, or he must refrain from sexual intercourse during the trial and until 90 days after completion of the trial. This is to prevent the possibility of a pregnancy from spermatocytes that can potentially be damaged by trial medication.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pila Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Henning Beck-Nielsen, Dr.

Role: PRINCIPAL_INVESTIGATOR

Odense University Hospital

Locations

Odense University Hospital

Odense, , Denmark

Countries

Denmark

Other Identifiers

PP-CT01

Identifier Type: -

Identifier Source: org_study_id